Pink SheetThe US Food and Drug Administration’s July advisory committee schedule includes a curious mix of vaccine safety reviews and the potentially triumphant return of a pulled multiple myeloma drug, in addi
ScripSanofi’s plans for rilzabrutinib continue apace with positive mid-stage data in IgG4-related disease ahead of a potential US approval in the summer for the potential ‘pipeline-in-a-product’ in immune
ScripRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com
ScripSpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f